文章摘要
刘丽娟,任鲜卉,王金香,康 涛,刘永良.自拟益气通阳活血方治疗阿尔茨海默病的临床研究[J].,2023,(21):4037-4041
自拟益气通阳活血方治疗阿尔茨海默病的临床研究
Clinical Study on the Treatment of Alzheimer's Disease with Self Designed Yiqi Tongyang Huoxue Formula
投稿时间:2023-06-16  修订日期:2023-07-11
DOI:10.13241/j.cnki.pmb.2023.21.007
中文关键词: 阿尔茨海默病  益气通阳活血方  认知功能  去甲肾上腺素  多巴胺  乙酰胆碱转移酶  日常生活活动能力
英文关键词: Alzheimer's disease  Yiqi Tongyang Huoxue Formula  Cognitive function  Norepinephrine  Dopamine  Acetylcholine transferase  Activities of daily living
基金项目:国家重点研发计划项目(2017YFC0907702)
作者单位E-mail
刘丽娟 中国人民解放军空军军医大学第一附属医院神经内科 陕西 西安 710032 15102935245@163.com 
任鲜卉 中国人民解放军空军军医大学第一附属医院神经内科 陕西 西安 710032  
王金香 中国人民解放军空军军医大学第一附属医院神经内科 陕西 西安 710032  
康 涛 中国人民解放军空军军医大学第一附属医院神经内科 陕西 西安 710032  
刘永良 天水市中医医院神经内科 甘肃 天水 741099  
摘要点击次数: 232
全文下载次数: 136
中文摘要:
      摘要 目的:分析自拟益气通阳活血方治疗阿尔茨海默病的临床效果。方法:选取2020年10月~2022年4月于中国人民解放军空军军医大学第一附属医院接受治疗的阿尔茨海默病患者104例,依据入院先后顺序编号,按单双号分为对照组(n=52)和研究组(n=52)。对照组进行常规西药治疗,研究组在此基础上进行自拟益气通阳活血方治疗。比较两组临床疗效、治疗前后中医证候积分、日常生活活动能力、认知功能、血清去甲肾上腺素(NE)、多巴胺(DA)、乙酰胆碱转移酶(ChAT)水平、β淀粉样蛋白前体(APP)、β淀粉样蛋白1-42(Aβ1-42)、丙二醛(MDA)、超氧化物歧化酶(SOD)水平,并比较两组安全性。结果:治疗后,两组中医证候积分均降低,且研究组显著低于对照组(P<0.05);研究组总有效率为94.23%,明显高于对照组的78.85%(P<0.05);治疗后,两组简易智能精神状态检查量表(MMSE)评分与蒙特利尔认知评估量表(MoCA)评分研究组均高于对照组(P<0.05);治疗后,两组barthel指数评分及日常生活能力量表(ADL)评分研究组均显著高于对照组(P<0.05);治疗后,两组DA、NE、ChAT水平均升高,且研究组明显高于对照组(P<0.05);治疗后,两组SOD水平升高,APP、Aβ1-42、MDA水平均降低(P<0.05),且与对照组相比研究组各指标变化更显著(P<0.05);两组治疗期间的不良反应均较轻微,经对症处理后均缓解,不良反应发生率比较无明显差异(P>0.05)。结论:自拟益气通阳活血方治疗阿尔茨海默病疗效显著,可降低中医证候积分,提高认知功能,调节NE、DA、ChAT水平,抑制APP、Aβ1-42水平,提高其日常生活活动能力,且安全性高。
英文摘要:
      ABSTRACT Objective: To analyze the clinical effect of Self designed Yiqi Tongyang Huoxue Formula in the treatment of Alzheimer's disease. Methods: A total of 104 patients with Alzheimer's disease who received treatment in The First Affiliated Hospital of the Chinese People's Liberation Army Air Force Military Medical University from October 2020 to April 2022 were selected. According to the order of admission, they were divided into control group (52 cases) and study group (52 cases) according to odd and even numbers. The control group was treated with conventional western medicine, and the study group was treated with Self designed Yiqi Tongyang Huoxue Formula on this basis. The clinical efficacy, traditional Chinese medicine syndrome scores, activities of daily living, cognitive function, serum norepinephrine (NE), dopamine (DA), acetylcholine transferase (ChAT) levels, amyloid beta protein precursor (APP), beta amyloid 1-42 (Aβ1-42), malondialdehyde (MDA), superoxide dismutase (SOD) levels, and the safety of the two groups was compared before and after treatment. Results: After treatment, the traditional Chinese medicine syndrome scores in both groups were decreased, and the research group was significantly lower than the control group (P<0.05); the study group's total effective rate was 94.23%, which was significantly higher than that of the control group(78.85%)(P<0.05). After treatment, the Mini-Mental State Examination (MMSE) score and the Montreal Cognitive Assessment Scale(MoCA) score in the study group were higher than those in the control group(P<0.05). After treatment, the barthel index score and the ADL score in the study group were significantly higher than those in the control group(P<0.05). After treatment, the levels of DA, NE and ChAT in the two groups were increased, and the research group was significantly higher than the control group(P<0.05). After treatment, the levels of SOD were increased, the levels of APP, Aβ1-42 and MDA in the two groups were decreased (P<0.05), and the changes of each index in the study group were more significant than those in the control group(P<0.05). The adverse reactions in the two groups during the treatment were mild, and they were relieved after symp tomatic treatment, and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Self designed Yiqi Tongyang Huoxue Formula has significant curative effect in the treatment of Alzheimer's disease. it can effectively reduce traditional Chinese medicine syndrome scores, and improve cognitive function, regulate the levels of NE, DA and ChAT, inhibit the levels of APP and Aβ1-42, enhance their ability to engage in daily activities and high safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭